Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Penumbra Inc (PEN)

Penumbra Inc (PEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,150,330
  • Shares Outstanding, K 39,243
  • Annual Sales, $ 1,404 M
  • Annual Income, $ 177,690 K
  • EBIT $ 189 M
  • EBITDA $ 207 M
  • 60-Month Beta 0.81
  • Price/Sales 9.41
  • Price/Cash Flow 78.26
  • Price/Book 9.23

Options Overview Details

View History
  • Implied Volatility 18.57% (-5.41%)
  • Historical Volatility 8.38%
  • IV Percentile 17%
  • IV Rank 12.53%
  • IV High 65.18% on 04/08/25
  • IV Low 11.90% on 02/26/26
  • Expected Move (DTE 18) 12.57 (3.81%)
  • Put/Call Vol Ratio 2.00
  • Today's Volume 15
  • Volume Avg (30-Day) 193
  • Put/Call OI Ratio 1.02
  • Today's Open Interest 7,710
  • Open Int (30-Day) 7,297
  • Expected Range 317.16 to 342.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.11
  • Number of Estimates 5
  • High Estimate 1.14
  • Low Estimate 1.07
  • Prior Year 0.83
  • Growth Rate Est. (year over year) +33.73%

Price Performance

See More
Period Period Low Period High Performance
1-Month
328.73 +0.15%
on 03/30/26
343.29 -4.10%
on 03/02/26
-15.18 (-4.41%)
since 02/27/26
3-Month
290.00 +13.52%
on 01/13/26
362.41 -9.16%
on 01/21/26
+12.24 (+3.86%)
since 12/26/25
52-Week
221.26 +48.79%
on 11/03/25
362.41 -9.16%
on 01/21/26
+61.65 (+23.04%)
since 03/28/25

Most Recent Stories

More News
2 Reasons to Avoid PEN and 1 Stock to Buy Instead

2 Reasons to Avoid PEN and 1 Stock to Buy Instead

PEN : 329.17 (-1.77%)
Why Boston Scientific's Big Dip Could Be a Bigger Opportunity

Boston Scientific's pending trial results could help to drive sales growth for years to come after lower-than-expected sales forecasts.

BSX : 64.39 (-6.91%)
PEN : 329.17 (-1.77%)
1 Growth Stock to Stash and 2 We Avoid

1 Growth Stock to Stash and 2 We Avoid

GTLB : 20.99 (+3.14%)
IIIN : 32.99 (-0.36%)
PEN : 329.17 (-1.77%)
3 Cash-Heavy Stocks That Fall Short

3 Cash-Heavy Stocks That Fall Short

TPC : 74.37 (-2.34%)
PEN : 329.17 (-1.77%)
CNC : 31.78 (-0.69%)
3 Cash-Producing Stocks We Approach with Caution

3 Cash-Producing Stocks We Approach with Caution

EXAS : 104.91 (+0.95%)
PEN : 329.17 (-1.77%)
HRB : 31.07 (-0.45%)
Are PEN, STKL, BCO, LNKB Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

STKL : 6.47 (+0.08%)
PEN : 329.17 (-1.77%)
LNKB : 8.19 (+1.89%)
BCO : 101.55 (+0.77%)
Penumbra (NYSE:PEN) Reports Bullish Q4 CY2025

Penumbra (NYSE:PEN) Reports Bullish Q4 CY2025

PEN : 329.17 (-1.77%)
Penumbra: Q4 Earnings Snapshot

Penumbra: Q4 Earnings Snapshot

PEN : 329.17 (-1.77%)
Penumbra, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

ALAMEDA, Calif. , Feb. 25, 2026 /PRNewswire/ -- Penumbra, Inc. ( NYSE: PEN ) , the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year...

BSX : 64.39 (-6.91%)
PEN : 329.17 (-1.77%)
1 Profitable Stock with Impressive Fundamentals and 2 We Brush Off

1 Profitable Stock with Impressive Fundamentals and 2 We Brush Off

NYT : 83.45 (+0.80%)
PEN : 329.17 (-1.77%)
BMI : 153.29 (+5.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access...

See More

Key Turning Points

3rd Resistance Point 339.28
2nd Resistance Point 338.33
1st Resistance Point 336.71
Last Price 329.17
1st Support Level 334.14
2nd Support Level 333.19
3rd Support Level 331.57

See More

52-Week High 362.41
Last Price 329.17
Fibonacci 61.8% 308.49
Fibonacci 50% 291.83
Fibonacci 38.2% 275.18
52-Week Low 221.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.